Valued at USD 4.61 billion in 2023, the Vaccine Contract Manufacturing Market is projected to reach USD 5.16 billion in 2024 and USD 13.16 billion by 2032, growing at a CAGR of 12.4% during the forecast period 2024–2032. The report segments the market by vaccine type, application, process and region. Competitive participants include Lonza Group, Catalent, Inc., Merck KGaA, Samsung...